U.S. markets closed

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
33.96+2.76 (+8.85%)
At close: 04:00PM EDT
34.25 +0.29 (+0.85%)
After hours: 06:18PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close31.20
Bid33.98 x 1000
Ask34.83 x 800
Day's Range31.85 - 34.17
52 Week Range26.81 - 84.83
Avg. Volume768,890
Market Cap3.595B
Beta (5Y Monthly)1.41
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ARWR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Arrowhead Pharmaceuticals, Inc.
    ARWR: Lowering target price to $35.00ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $35.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    7 days agoArgus Research
View more
  • Simply Wall St.

    Investing in Arrowhead Pharmaceuticals (NASDAQ:ARWR) five years ago would have delivered you a 982% gain

    Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders have seen the share price descend 19% over the month. But...

  • Motley Fool

    Arrowhead Pharmaceuticals (ARWR) Q3 2022 Earnings Call Transcript

    Thank you for joining us today to discuss Arrowhead's results for its fiscal 2022 third quarter ended June 30, 2022. With us today from management are president and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, our chief medical officer, who will provide an update on our mid-and later-stage clinical pipeline; Dr. James Hamilton, our senior vice president of Discovery and Translational Medicine, who will provide an update on our earlier stage programs; and Ken Myszkowski, our chief financial officer, who will give a review of the financials.

  • Reuters

    Drug reduces mutant protein that can lead to fibrosis in rare genetic liver disease

    The experimental Arrowhead Pharmaceuticals drug fazirsiran can reduce the accumulation of a mutant protein by 83% among people with alpha1-antitrypsin deficiency (AAT) disease, according to results from an open-label phase 2 trial involving 16 volunteers. The condition is a rare genetic liver disease wherein a mutant protein, known as Z-AAT, accumulates in the liver and can lead to fibrosis, then cirrhosis or portal hypertension, and eventually hepatic decompensation or hepatocellular carcinoma. There is no approved treatment.